Amplified Crosstalk Between Estrogen Binding and GFR Signaling Mediated Pathways of ER Activation Drives Responses in Tumors Treated with Endocrine Disruptors.
CONCLUSION: In tumor cells, the stabilization of genomic machinery and self-directed death may be achieved via a balanced activation of the AF1 and AF2 domains of ERs by natural estrogen treatment. In contrast, the blockade of either AF1 or AF2 domain by endocrine disruptors leads to toxic symptoms and unforeseeable tumor responses. PMID: 30027855 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - July 23, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

CS5931, a novel marine polypeptide, inhibits migration and invasion of cancer cells via interacting with enolase 1.
CONCLUSION: Our present study showed that the recombinant CS5931 could inhibit tumor invasion and metastasis via interacting with enolase 1, suggesting that the new marine polypeptide CS5931 possesses the potential to be developed as a novel anticancer agent. PMID: 29956637 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - July 1, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Targeting Metabolism to Counteract Tumor Angiogenesis: A Review of Patent Literature.
Authors: Petrillo S, Tolosano E, Munaron L, Genova T Abstract Massive vessel recruitment is required to sustain rapid tumor growth by delivering oxygen and nutrients. Current strategies to counteract angiogenesis are mostly aimed at reducing tumor vessel density. However, many of these drugs have been shown to trigger hypoxia, thus exacerbating tumor aggressiveness. Promising results come from a completely different approach based on the "normalization" of the endothelial layer and the consequent improvement of the vascular function. Since endothelial metabolism has proved essential in the regulation of t...
Source: Recent Patents on Anti-Cancer Drug Discovery - May 31, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Patent Selections.
Authors: PMID: 29788867 [PubMed - in process] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - May 25, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Evolving strategies for the treatment of T-cell lymphoma: a systematic review and recent patents.
CONCLUSION: Therapeutic strategies based on better molecular characterization of various histological types are certain to be used in the future. PMID: 29769011 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - May 18, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Synthesis, in-silico and in-- vitro cytostatic activity of new lipophilic derivatives of hydroxyurea.
CONCLUSION: Compound 7 with the suitable volume, log p and shape is the more or most active ligand against both cell lines. It is concluded or suggested that the size, shape and hydrophobic character of substituents strongly affect the pharmacodynamics and pharmacokinetic of these type of ligands. PMID: 29769012 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - May 18, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Recent Progress of Marine Polypeptides as Anticancer Agents Marine Polypeptides as Anticancer Agents.
CONCLUSION: Marine peptides possess chemical diversity and displays potent anticancer activity via targeting different signal pathways. Some of the marine peptides are promising to be developed as novel anticancer agents. PMID: 29708076 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - May 2, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Emerging Drugs for the Treatment of Breast Cancer Brain Metastasis: A Review of Patent Literature.
CONCLUSION: In this study we found 35 drug targets for metastasis to the brain in breast cancer, with 60% of them including only one patent, which establishes that this area of research is very recent, and that these targets have recently been linked to metastasis to the brain. On the other hand, 19 drug targets, among them VEGF, VEGFR2, CXCL12, and CXCR4, have been addressed for the first time until 6 years ago, confirming that the development of drugs for brain metastasis in breast cancer is an incipient area, but with interesting potential. Interestingly, the stage of inside the brain, was the stage with the lowest amou...
Source: Recent Patents on Anti-Cancer Drug Discovery - May 2, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Low dose of acacetin promotes breast cancer MCF-7 cells proliferation through the activation of ERK/ PI3K /AKT signaling pathway.
Conclusion Low dose of acacetin from 10^-3 μM to 1 μM promoted the proliferation of MCF-7 cells through the ERK/PI3K/AKT pathway and its downstream cyclin signaling, and this pathway is mainly mediated by the expression of ERα. PMID: 29676234 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - April 22, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Anti-Cancer Effect of ɑ-Solanine Mainly by Down-Regulating S100P Expression in Colorectal Cancer Cells.
CONCLUSION: These findings suggest that ɑ-solanine is a potential agent for the treatment of CRC, and the anti-tumor effect of ɑ-solanine in the CRC cells may be mediated at least partly by the downregulation of S100P. PMID: 29600769 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - April 1, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Stemness Phenotype in Tamoxifen Resistant Breast Cancer Cells may be induced by Interactions between Receptor Tyrosine Kinases and ER α-66.
CONCLUSION: Altogether, it seems that tumor cells express a stemness phenotype which tends to override anti-hormonal adjuvant therapies. Thus, targeting pathways that can lead to stemness can be an effective approach in reversing resistance. Since RTKs are overactivated and overexpressed in such cells, specialized targeted therapies suppressing RTKs would be a novel and effective way in restoring tamoxifen sensitivity in resistant breast cancer tumor cells. PMID: 29512469 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - March 9, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

PARP Inhibitors in Ovarian Cancer.
CONCLUSION: PARPis are valuable options in patients with recurrent ovarian cancer with promising activity in different stages of this disease. Further studies are required to better define optimal clinical settings, predictors of response beyond BRCA mutations and strategies to overcome secondary resistance of PARPis therapy in EOC. PMID: 29512470 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - March 9, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

TC > 0.05 as a Pharmacokinetic Parameter of Paclitaxel for Therapeutic Efficacy and Toxicity in Cancer Patients.
CONCLUSION: PTX TC>0.05 is a key pharmacokinetic parameter of PTX which should be monitored to optimize individual treatment in patients with solid tumors. PMID: 29512471 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - March 9, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Oral Submucous Fibrosis as an Overhealing Wound: Implications in Malignant Transformation.
CONCLUSION: Considering, Oral submucous fibrosis as an overhealing wound explains both pathogenesis and malignant transformation. Certainly, abnormalities in coagulation and fibrinolytic system are a common denominator in the profibrotic milieu and associated malignancy. PMID: 29485009 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - March 1, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

The Application of lncRNAs in Cancer Treatment and Diagnosis.
CONCLUSION: Current knowledge of lncRNAs presents prosperous prospects in cancer. However, functions of lncRNAs are still far from fully understood. Therefore, further study is need to advance imminent applications of these findings to the clinic. PMID: 29485010 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - March 1, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Lenvatinib in the Therapy of Aggressive Thyroid Cancer: State of the Art and New Perspectives with Patents Recently Applied.
CONCLUSION: On the base of the above mentioned considerations, it is necessary to prove the effectiveness of lenvatinib in the context of associated moderate to severe toxicities requiring frequent dose reduction and delays, and for this reason many interesting patents have been recently applied. PMID: 29468981 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - February 24, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation.
CONCLUSION: The promising effects of patented agents against IL-17A may open new opportunities to therapeutic intervention targeting at different levels of involvement in the pathogenesis of cancer and inflammatory diseases. PMID: 29468982 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - February 24, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Synthesis and DFT study on Hantzsch reaction to produce asymmetrical compounds of 1,4-dihydropyridine derivatives for P-glycoprotein inhibition as anticancer agent.
CONCLUSION: In this study, selected reactants by DFT calculation have increased yield of reaction from 36% to 74% without any catalyst. Diversity of products is noticeable topic. Racemic asymmetric compounds with R and S enantiomers have potential for enantiomeric separation. Each of these enantiomers could have different physiological effect. PMID: 29468983 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - February 24, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Anti-oxidants as chemopreventive agents in prostate cancer: A gap between preclinical and clinical studies.
Conclusion: A greater understanding of the molecular events associated with antioxidants will enhance the development of treatment and could result in better strategies for the chemoprevention of prostate cancer. Recent patents also suggest that anti-oxidant compounds can be effective for the prevention and the treatment of prostate cancer. PMID: 29446748 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - February 17, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Αnaplastic Lymphoma Kinase in Glioblastoma: Detection/Diagnostic Methods and Therapeutic Options.
CONCLUSION: ALK targeting holds promise as novel therapeutic approach in GBM, especially in combination schemes allowing multi-target therapy. Such schemes may incorporate detection-guided therapy and utilize next generation inhibitory compounds with improved central nervous system penetration. Moreover, identification of ALK-mediated molecular pathway(s) related to GBM carcinogenesis/pathology and putative therapy resistance is of high priority and warrants further exploitation. PMID: 29336268 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - January 18, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Reduced Lipocalin 2 Expression Contributes to Vincristine Resistance in Human Colon Cancer Cellsance in Human Colon Cancer Cells.
CONCLUSION: Overall, these results demonstrate that LCN2 plays an important role in VCR resistance and is a potential therapeutic target for this disease. PMID: 29268690 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - December 23, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Advances In the Discovery of Anthraquinone-Based Anticancer Agents.
CONCLUSION: A number of newly discovered natural products, the perspective directions for chemical modifications to optimize the anticancer properties, and novel intracellular targets demonstrate that anthracene-9,10-diones deserve further in-depth investigation as an important source of drug candidates. PMID: 29210664 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - December 8, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

PARP inhibitors in epithelial ovarian cancer.
Conclusion PARP inhibitors have emerged as an exciting new drug class in the treatment of epithelial ovarian cancer. Ongoing studies are aimed at improving our ability to identify ideal candidates for PARP inhibitor therapy, as well as to identify and target mechanisms of drug resistance, and novel combinatorial approaches. PMID: 29205122 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - December 6, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Brain Cancer: Implication to disease, therapeutic strategies and tumor targeted drug delivery approaches.
CONCLUSION: Novel strategies focused towards targeting drug substances specifically to brain tumor site would increase the therapeutic efficiency and reduce the toxicity of chemotherapeutics. PMID: 29189177 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - December 3, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Targeting Mevalonate Pathway in Cancer Treatment: Repurposing of Statins.
CONCLUSION: In this review article, we provide an overview of the current preclinical and clinical status of statins as antitumor agents. In addition, we evaluated various patents that describe the role of mevalonate pathway inhibitors and methods to determine if cancer cells are sensitive to statins treatment. PMID: 29189178 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - December 3, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy.
CONCLUSION: The review will describe a variety of specific inhibitor classes and conclude on recent and future therapeutic perspectives for this target. PMID: 29119937 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - November 11, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Adenosine receptor ligands on cancer therapy: A review of Patent Literature.
CONCLUSION: The promising anticancer effects mediated by adenosine receptor ligands put them in the forefront as new drug candidates. The present compilation can be worthy to medicinal chemists, pharmacologists, biochemists and other researchers focusing on the putative anticancer activity of adenosine receptor ligands. PMID: 29119938 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - November 11, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Nucleic Acid Sensing Machinery: Targeting Innate Immune System for Cancer Therapy.
Conclusion It is highly relevant to deepen the study of the nucleic acid-sensing mechanisms to develop new pharmacological approaches to engage these pathways within the tumour microenvironment. Indeed, further clarification will be functional to develop advanced anticancer strategies or to design new vaccines formulation. PMID: 29086701 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - November 2, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

The Epithelial-Mesenchymal Transition Pathway in Two Cases with Gastric Metastasis Originating from Breast Carcinoma, One with a Metachronous Primary Gastric Cancer.
CONCLUSIONS: In females with breast cancer, a possible metastasis in the stomach should be taken into account. Maspin and VSIG1 are not involved in breast cancer histogenesis. The Wnt/β-catenin signaling is not involved in the lobular carcinoma progression. The CD44/HER2 positivity in ductal carcinoma cells might indicate high risk of distant metastasis and low response to chemotherapy. PMID: 29090670 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - November 2, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

NLRP3 Inflammasome Activation Inhibitors in Inflammation-Associated Cancer Immunotherapy: An Update on the Recent Patents.
CONCLUSION: The vigorous effort to discover and develop agents to specifically inhibit NLRP3 inflammasome activation, may pave the way to therapeutic intervention targeting inflammasome-regulated pathways that are involved in the pathogenesis of various forms of cancer. PMID: 29076433 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - October 29, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Molecular modelling of berberine derivatives as inhibitors of human smoothened receptor and hedgehog signalling pathway using a newly developed algorithm on anti-cancer drugs.
CONCLUSION: This study predicted the role of berberine as an inhibitor of Smo receptor, suggesting its effectiveness in hedgehog signalling during cancer treatment. PMID: 28969581 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - October 5, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Strategies to Tackle Radiation Resistance by Penetrating Cancer Stem Cell Line of Scrimmage.
CONCLUSION: Many agents that directly or indirectly sensitize CSCs have been developed and some of them are on clinical trial. We expect that they will be used to enhance clinical radiation therapy in the future. PMID: 28971778 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - October 5, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

From a Better Understanding of the Mechanisms of Action of Histone Deacetylases Inhibitors to the Progress of the Treatment of Malignant Lymphomas and Plasma Cell Myeloma.
CONCLUSION: New and more effective histone deacetylases inhibitors gived alone or in combination are a solution for an improved response to the treatment of patients with relapsed/refractory lymphoproliferative disorders. PMID: 28933264 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - September 23, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Synergistic effect of epidermal growth factor receptor inhibitors and ionization radiation in cancer treatment.
CONCLUSION: The combination of EGFR inhibitor and ionizing radiation has synergistic effect and resulted in improvement of radiotherapy in patients. PMID: 28875828 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - September 7, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

BET Inhibitors as Anticancer Agents: A Patent Review.
CONCLUSION: The unmet needs and challenges associated with BET inhibition for cancer treatment have been portrayed in this review. An insight into the current developments and future prospects has been described as well. PMID: 28786345 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - August 10, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Chemical Space of FLT3 Inhibitors as the Potential Anti-AML Drugs.
Authors: Lan Q, Zhi Y, Heng H, Guo X, Liu H, Chen Y, Lu T, Lu S Abstract FLT3 is a member of receptor tyrosine kinase III family, expressed in normal bone marrow cells, early progenitor cells and hematopoietic stem cells. The aberrant expression and function of FLT3 are strongly related leukemia, especially acute myeloid leukemia. Its complex amino-acid residues mutations can induce ligand independent activation and downstream signaling transduction, leading to constant proliferation of hematological tumor cells with poor prognosis. Hence FLT3 serves as a promising target in AML chemotherapy. More recently, many sm...
Source: Recent Patents on Anti-Cancer Drug Discovery - July 28, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Pharmacological Inhibitors of NAD biosynthesis as potential anticancer agents.
Conclusion and Results: We have reviewed 16 relevant patents published since 2015, and summarized the chemical properties, mechanisms of action and proposed applications of the patented compounds. Without a better understanding of the properties of these compounds, their utility for further optimization and clinical use is unknown. For the compounds that have been tested using cell and mouse models of cancer, results look promising and clinical trials are currently ongoing to see if these results translate to improved cancer treatments. PMID: 28637419 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-...
Source: Recent Patents on Anti-Cancer Drug Discovery - June 25, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Immune cells act as promising targets for the treatment of bone metastasis.
CONCLUSION: Immune cells are instigated by tumor cells to enhance the occurrence and the development of bone metastasis. Taking full advantage of anti-tumor roles of immune cells may bring the promise of a possible cure for bone metastasis. PMID: 28595538 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - June 11, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

3D-QSAR (CoMFA, CoMSIA) and Molecular Docking Studies on Histone Deacetylase 1 Selective Inhibitors.
CONCLUSIONS: The obtained models showed a good predictive ability in both internal and external validation and could be used for designing new biaryl benzamides as potent HDAC1 inhibitors in cancer treatment. The amido and amine groups of benzamide part as scaffold and the bulk groups as a hydrophobic part were key factors to improve inhibitory activity of HDACIs. PMID: 28482791 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - May 10, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Poly (ADP-ribosyl) polymerase 1 inhibitors: A patent review.
CONCLUSION: The action mode of PARP1 inhibitors developed so far is competing with NAD+ for the catalytic site of PARP1. Using such inhibitors affects multiple NAD+-dependent enzymatic pathways, which results in secondary toxic effects. Designing inhibitors targeting other binding sites on the PARP1 protein is a strategy to bypass this pitfall. Analyzing the structure-activity relationships of active PARP1 inhibitors described in the patents, we conclude that the essential for the binding activity are amide group, aromatic ring or heterocyclic ring with rich electronics and heteroatom-substituted in the meta position of am...
Source: Recent Patents on Anti-Cancer Drug Discovery - May 10, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Indication of bevacizumab for cerebral radiation necrosis.
CONCLUSIONS: Symptoms are an indication of BVZ treatment for primary CRN. PMID: 28443515 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - April 27, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

In vitro collapsing colon cancer cells by selectivity of disulfiram-loaded charge switchable nanoparticles against cancer stem cells.
CONCLUSION: These patented coated nanoparticles were the most effective and selective for eradicating colon CSCs without insulting normal stem cells in comparison with disulfiram which was toxic to both normal and CSCs. This novel study that used charge switchable (hydrophilic) nanoparticles for targeting colon CSCs may represent a basis for future in vivo studies. PMID: 28440205 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - April 26, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Role of FoxM1 in the Progression and Epithelial to Mesenchymal Transition of Gastrointestinal Cancer.
Conclusion:FoxM1 is closely associated with tumorigenesis and plays an irreplaceable role in GI cancer EMT through crosstalk with TGF-β,Wnt signaling pathways and ncRNA. PMID: 28440206 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - April 26, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Epithelial Mesenchymal Transition in Cancer Progression: Preventive Phytochemicals.
CONCLUSION: EMT is a significant pharmacological target for developing preventive agents to combat pathological conditions like malignancy. Many of the phytochemicals cited in this review are being enrolled for different phases of clinical trials for their efficacy. In spite of the major limitations regarding bioavailability, sensitivity and tolerance of these compounds, their synthetic analogs, formulations and efficient drug delivery systems are also being attempted which will hopefully generate productive and promising results in near future. PMID: 28440207 [PubMed - as supplied by publisher] (Source: Recent Patents...
Source: Recent Patents on Anti-Cancer Drug Discovery - April 26, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Emerging Drugs for the Treatment of Cancer Pain: A review of Patent Literature in 2014.
CONCLUSION: In 2014, a number of patents were filed for treatment of pain among oncology patients. The great variety of chemical compounds presented indicates that there is a great variety in current research for cancer-related pain. The development of novel treatment options will hopefully lead to more effective therapies in the treatment of cancer-related pain. PMID: 28393711 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - April 12, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Editorial (Thematic Issue: Modulation of Proteostasis and Proteolytic Pathways as an Anti-Cancer Strategy).
Authors: Pereira DM PMID: 28284026 [PubMed - in process] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - March 13, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Activating mutations of ESR1, BRCA1 and CYP19 aromatase genes confer tumor response in breast cancers treated with antiestrogens.
CONCLUSION: Activating mutations affecting ERs play key roles in both the machinery of genome stabilization of healthy cells and the restoration of altered genetic pathways of DNA-repair in tumor cells. PMID: 28245776 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - March 3, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Integrin-targeted peptide- and peptidomimetic-drug conjugates for the treatment of tumors.
CONCLUSION: In spite of the promising features of the conjugates, none of them has entered clinical trials. New efforts are focused on innovative approaches in the field such as the synthesis of new integrin ligands able to target a single integrin type or the employment of nanoparticles based drug delivery systems. PMID: 28164756 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - February 7, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Docking and QSAR studies of 1,4-Dihydropyridine derivatives as anticancer agent.
CONCLUSION: The predictive ability of the models was found to be satisfactory and could be used for designing new 1,4-dihydropyridines as potent MDR inhibitors in cancer treatment. 1,4- dihydropyridine ring containing protonable nitrogen as scaffold could be proposed. Sulfur, ester, amide, acyle, ether … fragments are connected to a 1,4-dihydropyridine ring. Phenyl groups (with an electronegative substituent) as a lipophilic part are essential for the inhibitory effect. PMID: 28137213 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - February 1, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Marine Derived Anticancer Drugs Targeting Microtubule.
CONCLUSION: The marine derived MTAs hold great potential in the field of cancer therapeutics and are gradually advancing in the clinical set up. A deeper understanding of the molecular mechanisms combined with innovative therapeutic regimen would lead to great advances in the field. PMID: 28067173 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - January 12, 2017 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research